Practical microenvironment classification in diffuse large B cell lymphoma using digital pathology

Yuqing Wang(Army Medical University), Weili Zhao(Ruijin Hospital), Ken H. Young(Duke Medical Center), Pengpeng Xu(Hunan University), Zijun Y. Xu‐Monette(Duke University), Karolyn Au(University of Alberta), Shu-Ye Wang(Harbin Medical University), Hongmei Yi(Shanghai Jiao Tong University), Rongji Mu(Shanghai Jiao Tong University), Shuo Wang(Jiangnan University), Yan Dong(Shanghai Jiao Tong University), Haimin Xu(Shanghai Jiao Tong University), Jing Zhao(University of Copenhagen), Shuang Tian(Shanghai Jiao Tong University), Li Wang(University of Science and Technology of China), Yue Wang(Shanxi Medical University), Ying Qian(Shanghai Jiao Tong University), Di Fu(National University of Singapore)
Cell Reports Medicine
March 19, 2025
10.1016/j.xcrm.2025.102030
Cited by 8

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
|Blood|2017|429
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396